Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn has expanded its purchase and supply agreement with Indian company Natco to commercialize a third oral drug product for the treatment of cancer.
Subscribe to our email newsletter
The two companies believe that the agreement could make them significant market players in the oncology segment.
The drug product is indicated for the treatment of advanced breast cancer in post-menopausal women as a first-line therapeutic agent. Natco will be responsible for the development and manufacturing of the drug product, while Akorn will be responsible for marketing and distribution in the hospital, clinic, and home healthcare markets in the US and Canada.
“This oral anticancer product fits well with Akorn's overall strategy in the oncology arena. These select oral products are complementary to our generic injectable anticancer pipeline being developed with the Serum Institute of India,” stated Arthur Przybyl, Akorn's president and CEO.
Akorn said that the current market size for the drug product is approximately $490 million.